Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes
Clinical Pharmacology & Therapeutics2018Vol. 105(6), pp. 1338–1344
Citations Over TimeTop 10% of 2018 papers
Stephen G. Gonsalves, Robert T. Dirksen, Katrin Sangkuhl, Rebecca Pulk, Maria L. Alvarellos, Teresa T. Vo, Keiko Hikino, Dan M. Roden, Teri E. Klein, S. Mark Poler, Sephalie Y. Patel, Kelly E. Caudle, R. J. Gordon, Barbara W. Brandom, Leslie G. Biesecker
Abstract
The identification in a patient of 1 of the 50 variants in the RYR1 or CACNA1S genes reviewed here should lead to a presumption of malignant hyperthermia susceptibility (MHS). MHS can lead to life-threatening reactions to potent volatile anesthetic agents or succinylcholine. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of these agents in patients with these RYR1 or CACNA1S variants (updates at https://cpicpgx.org/guidelines and www.pharmgkb.org).
Related Papers
- → Autosomal Dominant Canine Malignant Hyperthermia Is Caused by a Mutation in the Gene Encoding the Skeletal Muscle Calcium Release Channel (RYR1 )(2001)90 cited
- → Exercise‐Induced Rhabdomyolysis and Stress‐Induced Malignant Hyperthermia Events, Association with Malignant Hyperthermia Susceptibility, and RYR1 Gene Sequence Variations(2013)42 cited
- → The use of guidelines to assess the risk of malignant hyperthermia in individuals with an RYR1 variant(2023)1 cited
- → Malignant Hyperthermia and Central Core Disease(2011)
- → Identification of a Novel Ryanodine Receptor Mutation Causing Malignant Hyperthermia(2013)